TransMedics Group is trading 10.1% down at $72.57 in pre-market action after its second-quarter report showed an earnings miss driven by a significant surge in spending.
- Revenue grew 21% year-over-year to approximately $190 million, but EPS of $0.41 missed expectations as operating expenses jumped 49%.
- The company raised the low end of its 2026 revenue guidance to $737 million–$757 million, though investors remain focused on margin pressure and rising costs.